These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Study on the effect of different doses of rosuvastatin on ventricular remodeling in patients with acute coronary syndrome after emergency percutaneous coronary intervention. Guo J; Zhang WZ; Zhao Q; Wo JS; Cai SL Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4457-4463. PubMed ID: 29077146 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan. Lee CH; Cheng CL; Kao Yang YH; Chao TH; Chen JY; Li YH Circ J; 2018 Feb; 82(3):747-756. PubMed ID: 29081474 [TBL] [Abstract][Full Text] [Related]
4. Raman chemical imaging for spectroscopic screening and direct quantification of falsified drugs. Rebiere H; Martin M; Ghyselinck C; Bonnet PA; Brenier C J Pharm Biomed Anal; 2018 Jan; 148():316-323. PubMed ID: 29080412 [TBL] [Abstract][Full Text] [Related]
9. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648 [TBL] [Abstract][Full Text] [Related]
10. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study. Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763 [TBL] [Abstract][Full Text] [Related]
11. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531 [TBL] [Abstract][Full Text] [Related]
12. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
13. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980 [TBL] [Abstract][Full Text] [Related]
14. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Levine GN; Bates ER; Bittl JA; Brindis RG; Fihn SD; Fleisher LA; Granger CB; Lange RA; Mack MJ; Mauri L; Mehran R; Mukherjee D; Newby LK; O'Gara PT; Sabatine MS; Smith PK; Smith SC J Am Coll Cardiol; 2016 Sep; 68(10):1082-115. PubMed ID: 27036918 [No Abstract] [Full Text] [Related]